TY - JOUR
T1 - Single CX3CL1-Ig DNA administration enhances T cell priming in vivo
AU - Iga, Mutsunori
AU - Boissonnas, Alexandre
AU - Mahé, Brice
AU - Bonduelle, Olivia
AU - Combadière, Christophe
AU - Combadière, Behazine
N1 - Funding Information:
M.I. and A.B. were supported by ORVACS fellowship (Objectif Recherches Vaccins SIDA) and La Fondation pour la Recherche Medicale, respectively. This work was supported by Young Investigator Awards “Agence National de Recherche” and “Cancéropole”. We thank Prs Brigitte Autran and Patrice Debre, Dr. Philippe Deterre for their helpful discussions.
PY - 2007/6/6
Y1 - 2007/6/6
N2 - Upon antigenic stimulation, establishment of adaptive immune responses that determines vaccine efficacy is dependent on efficient T cell priming. Here, single CX3CL1-Ig DNA administration, a unique ligand of CX3CR1, together with viral or tumor antigens induced a strong in vivo antigen-specific T cell proliferation and effector function that was enough efficient to protect against a tumor challenge. We also showed that early expression of CX3CL1-Ig and antigens in muscle and lymphoid organs induces an increased in vivo migration of myeloid CD14+CD11c+ DC but not lymphoid CD8α+CD11c+ DC at these sites. Thus, by effectively directing DC toward lymphoid organs to encounter T cells, CX3CL1-Ig become a new candidate that augments T cell priming and increases efficiency of vaccination.
AB - Upon antigenic stimulation, establishment of adaptive immune responses that determines vaccine efficacy is dependent on efficient T cell priming. Here, single CX3CL1-Ig DNA administration, a unique ligand of CX3CR1, together with viral or tumor antigens induced a strong in vivo antigen-specific T cell proliferation and effector function that was enough efficient to protect against a tumor challenge. We also showed that early expression of CX3CL1-Ig and antigens in muscle and lymphoid organs induces an increased in vivo migration of myeloid CD14+CD11c+ DC but not lymphoid CD8α+CD11c+ DC at these sites. Thus, by effectively directing DC toward lymphoid organs to encounter T cells, CX3CL1-Ig become a new candidate that augments T cell priming and increases efficiency of vaccination.
UR - http://www.scopus.com/inward/record.url?scp=34248376567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248376567&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.04.028
DO - 10.1016/j.vaccine.2007.04.028
M3 - Article
C2 - 17493713
AN - SCOPUS:34248376567
SN - 0264-410X
VL - 25
SP - 4554
EP - 4563
JO - Vaccine
JF - Vaccine
IS - 23
ER -
